奥氮平防治化疗相关性恶心呕吐的Meta分析
x
请在关注微信后,向客服人员索取文件
篇名: | 奥氮平防治化疗相关性恶心呕吐的Meta分析 |
TITLE: | |
摘要: | 目的:系统评价奥氮平防治化疗相关性恶心呕吐(CINV)的有效性和安全性,以为临床提供循证参考。方法:计算机检索Medline、PubMed、EMBase、Cochrane图书馆、Clinical Trials.gov、中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊数据库和万方数据库,收集奥氮平(试验组)对比其他药物或常规止吐方案(对照组)防治CINV有效性和安全性的随机对照试验(RCT),对符合纳入标准的研究进行资料提取,并采用改良的Jadad量表进行质量评价,再采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入19项RCT,合计1 794例患者。Meta分析结果显示,奥氮平能显著提高患者急性[RR=1.12,95%CI(1.06,1.18),P<0.001]、迟发性[RR=1.26,95%CI(1.14,1.39),P<0.001]、全程[RR=1.62,95%CI(1.32,1.99),P<0.001]和爆发性[RR=2.05,95%CI(1.47,2.86),P<0.001] CINV完全控制率,与对照组比较差异均有统计学意义;两组患者疲倦、头晕、嗜睡和便秘发生率比较,差异均无统计学意义(P>0.05)。结论:奥氮平防治CINV的有效性和安全性均较好,可推荐用于其他止吐方案无效的爆发性与难治性CINV的治疗。此外,由于奥氮平防治CINV属于超说明书用药,临床治疗需综合考虑化疗方案及患者的治疗意愿。 |
ABSTRACT: | OBJECTIVE:To systematically review the effectiveness and safety of olanzapine in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), and provide evidence-based reference for clinical treatment. METHODS: Retrieved from Medline, PubMed, EMBase, Cochrane Library, Clinical Trials.gov, CBM, CJFD, VIP and Wanfang Database, randomized controlled trials (RCT) about olanzapine (test group) versus other drugs or conventional antiemetic regimen (control group) in the prevention and treatment of CINV were collected, Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation by modified Jadad. RESULTS: Totally 19 RCTs were included, involving 1 794 patients. Results of Meta-analysis showed, olanzapine can significantly improve the complete control rate of patients with acute CINV [RR=1.12,95%CI(1.06,1.18),P<0.001], delayed CINV[RR=1.26,95%CI(1.14, 1.39),P<0.001], overall CINV [RR=1.62,95%CI(1.32, 1.99),P<0.001] and breakthrough CINV[RR=2.05,95%CI(1.47, 2.86),P<0.001], there were significant differences between 2 groups; there were no significant differences in the incidence of tiredness, dizziness, lethargy and constipation(P>0.05). CONCLUSIONS:Olanzapine is safe and effective in the prevention and treatment of CINV and can be recommended in treating breakthrough and refractory CINV. Besides, olanzapine in the prevention and treatment of CINV belongs to “off-label use”, so the clinicians should have a comprehensive consideration of chemotherapy and patients’ consent. |
期刊: | 2016年第27卷第15期 |
作者: | 梁瑶,谢铮铮,杜朝阳,赵莹,孙路路 |
AUTHORS: | LIANG Yao,XIE Zhengzheng,DU Zhaoyang,ZHAO Ying,SUN Lulu |
关键字: | 奥氮平;化疗;恶心;呕吐;Meta分析;系统评价 |
KEYWORDS: | Olanzapine; Chemotherapy; Nause; Vomiting; Meta-analysis; Systematic review |
阅读数: | 405 次 |
本月下载数: | 2 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!